This information is being published only for the benefit of the patients and for doctors. You are requested to contact the details given directly. ORDI can facilitate meeting and not responsible for any thing related to the trials or outcome.
1) Clinical trial on – Gaucher disease (GD)
Place : Jaslok Hospital and Research Centre, Mumbai
Study – This study is being conducted for the drug “Orphazyme A/S”
Eligibility : The study population required for the study is Male or Female patients between 4- 60 years with diagnosis of GD type 1 or GD type 3.
This is a placebo-controlled, randomised, double-blinded trial for GD type I and 3. Patients who are randomised to receive placebo will be further randomised to receive arimoclomol 300 mg/day, 600 mg/day, or 1200 mg/day (provided there are no safety concerns) on a 1:1:1 basis during the open-label extension phase of the trial.
Duration: The duration of the double-blinded, placebo-controlled period of the trial is 6 months. The open-label extension phase will continue until arimoclomol has received marketing authorisation (MA) in India or availability of relevant data from the development program.
Main inclusion criteria:
- Be able to understand and voluntarily sign the informed consent form.(patient/parent)
- A diagnosis of GD, either Type 1 or Type 3, with a GBA enzyme activity of 0% to 15% of normal activity. Note that the local laboratory test result will be used at inclusion.
- For GD3, at least 1 neurological symptom.
- Age ≥ 4 and ≤ 60 years at the time of enrolment.
- Plasma or serum chitotriosidase levels > 3000 nmol/mL/h.
- Either naïve to treatment for GD or has not received treatment (investigational or authorised/approved such as enzyme replacement therapy or substrate reduction therapy, also including procedures such as blood transfusions and splenectomy) for GD within 4 months prior to trial entry.
- Ability to comply with the protocol-specified procedures/evaluations and scheduled visits (if platelet counts are < 50000 platelets per microlitre of circulating blood lumbar puncture should not be performed).
- Ability to travel to the investigational clinical trial site repeatedly (screening, baseline, 1, 3, 6, and 7 months, then every 6 months during the extension part) for evaluation and follow-up.
- All sexually active female patients of child-bearing potential (postmenarcheal) must use highly effective contraception during the trial and until 1 week after the last dose of IMP.
IMP NOTE
All sexually active male patients with female partners of child-bearing potential (postmenarcheal) must use a condom with or without spermicide in addition to the birth control used by their partners during the trial and until 3 months after the last dose of IMP.
Main exclusion criteria:
- Recipient of a liver transplant or planned liver transplantation during the course of the trial.
- Splenectomy within 4 months of trial entry or planned splenectomy during the course of the trial.
- Aspartate aminotransferase and/or alanine aminotransferase greater than 3 times the upper limit of normal for age and sex [central laboratory assessment]).
- Serum creatinine level greater than 1.5 times the upper limit of normal (central laboratory assessment).
- The patient has received any IMP within 30 days prior to trial entry (Note that IMP for GD should not have been taken within the last 4 months prior to enrolment, as per entry criterion #6).
- The patient is pregnant and/or breastfeeding.
- If, in the opinion of the Principal Investigator, the patient has a clinical condition that is not compatible with the requirements of this protocol.
- Body weight < 10 kg.
Contact Details:
Dr Aabha Nagral
Gastroenterologist
Special interest – Hepatology, Pediatric Hepatology and Liver Transplantation
Apollo Hospital, Navi Mumbai and Jaslok Hospital, Mumbai
For appointments
(022) 24222160 after 4pm (Monday to Friday)
